Plain-English translation of NCT06567977 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →This is an observational study—not a test of a new drug, but rather a real-world look at how patients respond to Trimbow®, a combination inhaler that delivers three medications in one device. Researchers want to understand how well this medication controls asthma symptoms, improves lung function, and affects patients' daily lives when used in regular medical practice, rather than in a controlled research setting.
Although this medication has shown promise in controlled clinical trials, doctors and researchers don't yet know how well it works for patients in everyday life or how it affects people's symptoms, quality of life, and medication adherence. This study will help fill that gap and guide future treatment decisions.
You would continue taking your prescribed inhaler as normal—no extra medications or procedures are involved. The study team will monitor you over time by checking your asthma control through questionnaires, measuring your lung function with standard breathing tests, tracking your quality of life, and reviewing your medical records to see how well the treatment is working and whether you have any asthma flare-ups. Visits and monitoring schedules will follow your regular doctor's appointments.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Poland
Sponsor
Chiesi Poland Sp. z o.o.
Collaborators
Gesellschaft für Therapieforschung mbH
Enrollment target
~60 participants
Started
August 2024
Primary completion
March 2025
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tomasz Debowski, Md Phd
Chiesi Poland Sp. z o.o.